Merck & Co., Inc. (MRK) Shares Bought by MAI Capital Management
MAI Capital Management lifted its holdings in shares of Merck & Co., Inc. (NYSE:MRK) by 22.9% in the fourth quarter, HoldingsChannel reports. The institutional investor owned 70,861 shares of the company’s stock after acquiring an additional 13,207 shares during the period. MAI Capital Management’s holdings in Merck & Co., Inc. were worth $3,987,000 at the end of the most recent reporting period.
Several other institutional investors have also bought and sold shares of the company. Vanguard Group Inc. raised its holdings in shares of Merck & Co., Inc. by 1.7% during the 2nd quarter. Vanguard Group Inc. now owns 194,144,317 shares of the company’s stock worth $12,442,709,000 after buying an additional 3,312,459 shares in the last quarter. BlackRock Inc. raised its holdings in shares of Merck & Co., Inc. by 1.0% during the 2nd quarter. BlackRock Inc. now owns 184,997,390 shares of the company’s stock worth $11,856,484,000 after buying an additional 1,834,500 shares in the last quarter. Franklin Resources Inc. raised its holdings in shares of Merck & Co., Inc. by 3.1% during the 2nd quarter. Franklin Resources Inc. now owns 27,019,572 shares of the company’s stock worth $1,731,684,000 after buying an additional 801,033 shares in the last quarter. Ameriprise Financial Inc. raised its holdings in shares of Merck & Co., Inc. by 7.5% during the 3rd quarter. Ameriprise Financial Inc. now owns 23,515,877 shares of the company’s stock worth $1,505,621,000 after buying an additional 1,631,013 shares in the last quarter. Finally, Boston Partners raised its holdings in shares of Merck & Co., Inc. by 0.8% during the 3rd quarter. Boston Partners now owns 18,730,874 shares of the company’s stock worth $1,199,338,000 after buying an additional 145,744 shares in the last quarter. 74.79% of the stock is owned by institutional investors.
In other Merck & Co., Inc. news, insider Weir Mirian M. Graddick sold 60,000 shares of the company’s stock in a transaction dated Tuesday, January 16th. The stock was sold at an average price of $61.63, for a total value of $3,697,800.00. Following the sale, the insider now owns 101,484 shares in the company, valued at approximately $6,254,458.92. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, Director Wendell P. Weeks sold 5,000 shares of the company’s stock in a transaction dated Friday, February 9th. The shares were sold at an average price of $53.57, for a total value of $267,850.00. Following the completion of the sale, the director now owns 5,100 shares in the company, valued at approximately $273,207. The disclosure for this sale can be found here. Insiders sold a total of 82,500 shares of company stock worth $5,026,025 in the last quarter. Corporate insiders own 0.25% of the company’s stock.
Shares of Merck & Co., Inc. (MRK) opened at $55.37 on Wednesday. Merck & Co., Inc. has a 52-week low of $53.12 and a 52-week high of $66.41. The company has a market capitalization of $149,290.00, a PE ratio of 30.42, a price-to-earnings-growth ratio of 2.27 and a beta of 0.81. The company has a debt-to-equity ratio of 0.62, a current ratio of 1.33 and a quick ratio of 1.06.
Merck & Co., Inc. (NYSE:MRK) last released its quarterly earnings results on Friday, February 2nd. The company reported $0.98 EPS for the quarter, beating analysts’ consensus estimates of $0.94 by $0.04. Merck & Co., Inc. had a return on equity of 28.61% and a net margin of 6.40%. The firm had revenue of $10.43 billion for the quarter, compared to analyst estimates of $10.48 billion. During the same quarter in the previous year, the company posted $0.89 EPS. The business’s revenue was up 3.1% on a year-over-year basis. equities research analysts expect that Merck & Co., Inc. will post 4.16 earnings per share for the current fiscal year.
Merck & Co., Inc. announced that its board has approved a share repurchase plan on Tuesday, November 28th that authorizes the company to repurchase $10.00 billion in outstanding shares. This repurchase authorization authorizes the company to buy shares of its stock through open market purchases. Stock repurchase plans are often a sign that the company’s management believes its stock is undervalued.
The business also recently declared a quarterly dividend, which will be paid on Friday, April 6th. Shareholders of record on Thursday, March 15th will be given a $0.48 dividend. The ex-dividend date of this dividend is Wednesday, March 14th. This represents a $1.92 dividend on an annualized basis and a dividend yield of 3.47%. Merck & Co., Inc.’s dividend payout ratio (DPR) is presently 105.49%.
Merck & Co., Inc. Profile
Merck & Co, Inc is a global healthcare company. The Company offers health solutions through its prescription medicines, vaccines, biologic therapies and animal health products. It operates through four segments: Pharmaceutical, Animal Health, Healthcare Services and Alliances. The Company’s Pharmaceutical segment includes human health pharmaceutical and vaccine products marketed either directly by the Company or through joint ventures.
Want to see what other hedge funds are holding MRK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Merck & Co., Inc. (NYSE:MRK).
Receive News & Ratings for Merck & Co. Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Co. Inc. and related companies with MarketBeat.com's FREE daily email newsletter.